相关实验视频

Updated: May 2, 2026

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

[基于非标代谢的耐尼拉巴里布卵巢癌细胞的代谢特征]

H Lin¹, H Y Jin¹, W G Lyu¹

¹Department of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Zhejiang Key Laboratory of Maternal and Infant Health, Zhejiang Provincial Clinical Research Center for Gynecological Diseases, Hangzhou 310006, China.

Zhonghua fu chan ke za zhi

|August 25, 2025

概括

这项研究确定了耐尼拉巴里布的卵巢癌细胞系 (A2780-NiraR),表现出改变的形态和更慢的增殖. 在卵巢癌中,阿基尼代谢途径被确定为克服尼拉帕里布耐药性的潜在目标.

科学领域:

癌症学
分子生物学
代谢学

背景情况:

卵巢癌仍然是癌症相关死亡的主要原因.
药物耐药性的发展,特别是对PARP抑制剂的耐药性,是一个重大的临床挑战.
了解耐药性的生物和代谢基础对于开发有效的治疗策略至关重要.

研究的目的:

建立耐尼拉巴里布的卵巢癌细胞系 (A2780-NiraR).
描述耐药细胞系的生物特征.
探索与尼拉巴里布耐药性相关的代谢特征.

主要方法:

在A2780卵巢癌细胞中使用度梯度方法诱导耐尼拉巴.
评估了形态变化,IC50值,细胞增殖和细胞周期分布.
进行非向代谢分析 (UPLC/ HRMS) 和KEGG途径分析以确定差异代谢物和丰富途径.

主要成果:

在G0/ G1阶段,A2780-NiraR细胞表现出形态变化,尼拉帕里布IC50显著增加,增殖速度减慢,细胞周期停止.
代谢分析发现了44种不同的代谢物,其中皮罗利碳酸,L-lysine和1- pyrroline-4- hydroxy-2- carboxylate的含量增加.
丰富的代谢途径包括氨酸代谢,纯氨酸代谢和胺代谢.

结论:

已确定的A2780-NiraR细胞系显示出一种稳定的耐尼拉帕里布的表型.
代谢途径,特别是氨酸代谢,是提高尼拉帕里布在卵巢癌中的疗效的潜在目标.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Author Spotlight: Advancing Metabolomics Analysis of Rare Hematopoietic Stem Cells

Author Spotlight: Advancing Metabolomics Analysis of Rare Hematopoietic Stem Cells

Published on: February 23, 2024

相关概念视频

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...